 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summary
Intuitive Surgical
ISRG
conference date: October 18, 2016 @ 1:30 PM Pacific Time
for quarter ending: September 30, 2016 (third quarter, Q3 2016)
Overview: Sorry, I missed this one, on vacation, don't see getting back to it.
Basic data (GAAP):
Revenue was $ million, up % sequentially from $670.1 million and up % from $ million in the year-earlier quarter.
Net income was $ million, up % sequentially from $184.5 million, and up % from $ million year-earlier.
EPS (earnings per share, diluted) were $, up % sequentially from $4.71 and up % from $ year-earlier.
Guidance:
Conference Highlights:
Intuitive Surgical shipped da Vinci Surgical Systems, ? sequentially from 130, and up from in the year-earlier quarter.
Procedures using da Vinci systems in Q2 grew
Revenue from Da Vinci system sales was $ million, up % sequentially from $202.7 million, and up % from $ million year-earlier. $ million average price.
Revenue from instruments and accessories was $ million, up % sequentially from $339 million, and up % from $ million year-earlier. $ per procedure average.
Revenue from services was $ million was up % sequentially from $128.1 million and up % y/y from $ million.
Non-GAAP numbers: Net income was $ million, up % sequentially from $220.4 million and up % from $ million year-earlier. Non-GAAP EPS was $, up % sequentially from $5.62, and up % from $ year-earlier. % gross margin. Non-GAAP numbers exclude trade out revenues. Share based compensation expense was $ million.
The cash and equivalents balance ended at $ billion, up sequentially from $4.22 billion. There is no debt. Nothing was spent on stock buybacks in the quarter.
Cost of revenue was $ million, leaving gross profit of $ million. Operating expenses of $ million included: $ million for selling, general, and administrative; $ million for research and development. Leaving income from operations of $ million. Interest income was $ million. Income tax expense $ million.
Q&A:
Intuitive Surgical Conference Summaries Main Page
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| ALXN |
| AMAT |
| AMD |
| AMGN |
| BIIB |
| BIND |
| CLDX |
| CELG |
| EPZM |
| GILD |
| GLYC |
| HNSN |
| INO |
| INTC |
| ISRG |
| JUNO |
| MACK |
| MCHP |
| MDVN |
| MYL. |
| NVDA |
| OPXA |
| PLX |
| REGN |
| SGEN |
| XLNX |
| XLRN |
Disclaimer: My analyst call summaries may include both our condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.
Copyright 2016 William P. Meyers